|
|
News Breaks | | | | November 12, 2012 | | 07:00 EDT |  | ACHN | Achillion provides update on clinical HCV development programs
Achillion Pharmaceuticals provided an update on the sovaprevir and ACH-3102 clinical development programs and announced new Phase 1b clinical trial results on ACH-2684. The completion of a drug-drug interaction study evaluating the combination of sovaprevir and ACH-3102. The study, conducted in 24 healthy volunteers, concluded that there was no interaction between the two investigational compounds and that both sovaprevir and ACH-3102 were safe and well-tolerated by study participants with no significant adverse events reported. | |
|
News For ACHN From The Last 14 Days Check below for free stories on ACHN the last two weeks. |
|
|
| May 16, 2013 | | 10:30 EDT |  | ACHN | Achillion management to meet with Maxim
 Subscribe for More Information | | | May 15, 2013 | | 06:06 EDT | | ACHN | Achillion appoints Dr. David Apelian as Chief Medical Officer
Achillion (ACHN) appointed David Apelian, M.D., Ph.D., MBA, to the position of Executive VP and Chief Medical Officer, effective May 28. Dr. Apelian wll assume responsibility for the clinical development of Achillion's portfolio of compounds to treat HCV. In addition, Achillion also expanded its clinical operations group with the recent addition of Kevin Kucharski, formerly head of clinical operations at Pharmasset (VRUS), who will serve as Senior VP of Clinical Operations. | |
|
|
|
|
|
|
